Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Agios Pharmaceuticals (AGIO) EBITDA: 2011-2024

Historic EBITDA for Agios Pharmaceuticals (AGIO) over the last 14 years, with Dec 2024 value amounting to -$425.7 million.

  • Agios Pharmaceuticals' EBITDA fell 13.67% to -$116.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$475.6 million, marking a year-over-year decrease of 16.86%. This contributed to the annual value of -$425.7 million for FY2024, which is 8.75% down from last year.
  • According to the latest figures from FY2024, Agios Pharmaceuticals' EBITDA is -$425.7 million, which was down 8.75% from -$391.5 million recorded in FY2023.
  • Agios Pharmaceuticals' EBITDA's 5-year high stood at -$335.9 million during FY2020, with a 5-year trough of -$425.7 million in FY2024.
  • For the 3-year period, Agios Pharmaceuticals' EBITDA averaged around -$402.1 million, with its median value being -$391.5 million (2023).
  • Data for Agios Pharmaceuticals' EBITDA shows a maximum YoY declined of 12.65% (in 2021) over the last 5 years.
  • Agios Pharmaceuticals' EBITDA (Yearly) stood at -$335.9 million in 2020, then decreased by 12.65% to -$378.4 million in 2021, then declined by 2.81% to -$389.0 million in 2022, then declined by 0.63% to -$391.5 million in 2023, then fell by 8.75% to -$425.7 million in 2024.